Germany consolidates itself as world leader in pharma, says CPhI
Germany has been ranked as Europe’s preeminent pharma industry, according to data drawn from the CPhI Annual Report and includes opinions from over 350 international pharma companies.
The ‘CPhI Pharma Index’ is the only annually produced perception ranking of the world’s top performing countries. It provides vital insights into the world’s leading pharma economies across all attributes, and indicates which markets have the greatest business prospects and growth potential.
The results see Germany consolidate its status as an elite pharmaceutical market, finishing ahead of its European rivals in active pharmaceutical ingredients (API) manufacturing (7.88), competitiveness (6.48), innovation (7.49) finished product manufacturing (8.02), and growth potential (6.92).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze